Association of Concomitant Proton Pump Inhibitor Use with Survival Outcomes During CDK4/6 Inhibitor Therapy for Breast Cancer

BACKGROUND: Concomitant use of proton pump inhibitors (PPIs) is common during cyclin-dependent kinase 4/6 (CDK4/6) inhibitor therapy. We examined the association between concomitant PPI use and survival outcomes in patients with hormone receptor-positive, HER2-negative breast cancer. METHODS: We conducted a nationwide retrospective cohort study using Korean National Health Insurance Service data. PPI exposure was defined as at least 30 days of overlapping PPI and CDK4/6 inhibitor prescriptions during the first 90 days after CDK4/6 inhibitor initiation. Patients who died or experienced a real-world progression-free survival (rwPFS) event during this window were excluded. Follow-up for rwPFS and overall survival (OS) began at day 90. We used stabilized inverse probability of treatment weighting and weighted Cox models to estimate hazard ratios (HRs). RESULTS: Of 7,208 patients who initiated CDK4/6 inhibitor therapy, 6,435 entered the landmark cohort, including 574 (8.9%) who met the PPI exposure definition. After weighting, absolute standardized mean differences were below 0.10 for all included covariates. Concomitant PPI use was associated with shorter rwPFS (HR, 1.33; 95% confidence interval [CI], 1.16-1.51) and OS (HR, 1.54; 95% CI, 1.34-1.76). The unweighted estimates were in the same direction (rwPFS HR, 1.32; OS HR, 1.65). CONCLUSIONS: Concomitant PPI use was associated with shorter rwPFS and OS among patients who remained alive and event-free through day 90. Residual confounding, including differences in the indications for PPI use, may contribute to these associations. Further studies are needed to clarify their clinical significance.

Authors

Institutions

Publication Details

Journal
The Oncologist
Published
2026-11-20
DOI
https://doi.org/10.1093/oncolo/oyag463
Primary Topic
Advanced Breast Cancer Therapies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Association of Concomitant Proton Pump Inhibitor Use with Survival Outcomes During CDK4/6 Inhibitor Therapy for Breast Cancer

Jeong Won Jin, Sungmin Park, Kyung-Hun Lee, Ji Sung Lee
The Oncologist
Advanced Breast Cancer Therapies
article

Association of Concomitant Proton Pump Inhibitor Use with Survival Outcomes During CDK4/6 Inhibitor Therapy for Breast Cancer

Jeong Won Jin, Sungmin Park, Kyung-Hun Lee, Ji Sung Lee
article en

Abstract

BACKGROUND: Concomitant use of proton pump inhibitors (PPIs) is common during cyclin-dependent kinase 4/6 (CDK4/6) inhibitor therapy. We examined the association between concomitant PPI use and survival outcomes in patients with hormone receptor-positive, HER2-negative breast cancer. METHODS: We conducted a nationwide retrospective cohort study using Korean National Health Insurance Service data. PPI exposure was defined as at least 30 days of overlapping PPI and CDK4/6 inhibitor prescriptions during the first 90 days after CDK4/6 inhibitor initiation. Patients who died or experienced a real-world progression-free survival (rwPFS) event during this window were excluded. Follow-up for rwPFS and overall survival (OS) began at day 90. We used stabilized inverse probability of treatment weighting and weighted Cox models to estimate hazard ratios (HRs). RESULTS: Of 7,208 patients who initiated CDK4/6 inhibitor therapy, 6,435 entered the landmark cohort, including 574 (8.9%) who met the PPI exposure definition. After weighting, absolute standardized mean differences were below 0.10 for all included covariates. Concomitant PPI use was associated with shorter rwPFS (HR, 1.33; 95% confidence interval [CI], 1.16-1.51) and OS (HR, 1.54; 95% CI, 1.34-1.76). The unweighted estimates were in the same direction (rwPFS HR, 1.32; OS HR, 1.65). CONCLUSIONS: Concomitant PPI use was associated with shorter rwPFS and OS among patients who remained alive and event-free through day 90. Residual confounding, including differences in the indications for PPI use, may contribute to these associations. Further studies are needed to clarify their clinical significance.

The Oncologist
Cancer Research Institute (US), Asan Medical Center (KR), Samsung Medical Center (KR), Seoul National University Hospital (KR), Chungbuk National University Hospital (KR)
Advanced Breast Cancer Therapies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon
Association of Concomitant Proton Pump Inhibitor Use with Survival Outcomes During CDK4/6 Inhibitor Therapy for Breast Cancer — Jeong Won Jin, Sungmin Park, et al. · The Oncologist (2026) | TGRS Research Map | TGRS